45 46 While one dimensional 1 H nuclear magnetic resonance (1D 1 H-NMR) spectroscopy is one of the most 47 important and convenient method for measuring conformation change in biomacromolecules, 48 characterization of protein dynamics in large membrane protein complexes by 1D 1 H-NMR remains 49 challenging, due to the difficulty of spectra assignment, low signal-to-noise ratio (S/N) and the need for large 50 amount of protein. Here we report the site-specific incorporation of 4-trimethylsilyl phenylalanine (TMSiPhe) 51 into proteins, through genetic code expansion in Escherichia coli cells, and the measurement of multiple 52 conformational states in membrane protein complex by 1D 1 H-NMR. The unique up-field 1 H-NMR chemical 53 shift of TMSiPhe, highly efficient and specific incorporation of TMSiPhe enabled facile assignment of the 54 TMSiPhe 1 H-NMR signal, and characterization of multiple conformational state in a 150 kilodalton (kD) 55 membrane protein complex, using only 5 μM of protein and 20 min spectra accumulation time. This highly 56 efficient and convenient methods should be broadly applicable for the investigation of dynamic conformation 57 change of protein complexes. 58 59
endogenous 1 H-NMR signals from β-arrestin-1, providing a distinct NMR probe for the examination of the 149 structural dynamics of a specific site (Figure 1e and Figure S5 ). Notably, the 1 H-NMR signal of TMSiPhe-150 incorporated arrestin can be detected at concentrations as low as 5 μM very rapidly (in less than 20 min) using a 151 950 MHz NMR spectrometer. This high sensitivity is due to the nine equivalent proton present in the TMS group, 152 and the usage of a high-field NMR spectrometer. By contrast, the large chemical shift anisotropy (CSA) of 19 F in 153 general limit the 19 F-NMR studies of proteins to NMR spectrometers lower than 600 MHz. The high sensitivity of 154 the TMSiPhe probe is important for 1D 1 H-NMR studies, especially for large membrane proteins complexes since 155 they are prone for aggregation in high concentration. To investigate the molecular basis of the selective recognition of TMSiPhe by TMSiPheRS, we crystallized 160
TMSiPheRS and analyzed the structures by X-ray crystallography. The crystal structures of TMSiPheRS alone and 161 the complex of TMSiPheRS with TMSiPhe were determined at 1.8 Å and 2.1 Å, respectively (Table S2 ). The 2Fo-162
Fc annealing omit map of the TMSiPheRS/TMSiPhe complex unambiguously assigned the electron density for 163 TMSiPhe (Figure 2a ). Introduction of the TMS group significantly increased the volume of the amino acid substrate 164 by approximately 60% (Figure 2b ). To compensate for this substantial change in volume, three residues, namely, 165
Asp158, Ile159 and Val164, were replaced by the smallest amino acid Gly, and Tyr32 and Leu65 were substituted 166 by the relatively small residues His32 and Val65, respectively ( Figure 2b-2c and Figure S3 ). We then compared the 167 crystal structure of the TMSiPheRS/TMSiPhe complex with that of apo TMSiPheRS. Compared to the structure of 168 TMSiPheRS alone, we observed a dramatic 120-degree rotation of histidine 32 in response to TMSiPhe binding. 169 Moreover, Leu162 rotated approximately 42 degrees to form hydrophobic interactions with the methyl groups of 170 TMSiPhe (Figure 2d ). Altogether, Gly34, Val65, Gln70, Phe108, Gln109, Tyr151, Gln155, Gly158, Gly159, 171 Gln173 and His177 defined a hydrophobic pocket for the accommodation of and specific interactions with the 172 phenyl ring and TMS group of TMSiPhe (Figure 2c and Figure S3 ). These observations provided a structural basis 173 for specific and efficient incorporation of TMSiPhe using evolved TMSiPheRS. 174 175 Incorporation of TMSiPhe at specific sites in β-arrestin-1 enabled characterization of β-arrestin-1 activation 176 177 We then incorporated TMSiPhe into functionally relevant structural motifs of β-arrestin-1, the key signal 178 transducer downstream of almost all 800 GPCRs encoded in the human genome, which functions not only by 179 desensitizing membrane receptors but also by mediating independent downstream signaling after receptor 180 activation 12, [14] [15] [16] [17] [18] [19] [20] [21] [22] 30 (Figure 3a and 3b) . Although the functions of many arrestin-mediated receptors have been 181 identified and certain motifs of arrestin are suspected to be involved in specific signaling pathways (Table S3) , the 182 correlation between the conformational states of these arrestin motifs and selective receptor functions remains to be elucidated. Incorporation of TMSiPhe into β-arrestin-1 at specific positions, including the receptor-phosphate-184 binding site (Y21), the finger loop (Y63), the hinge region (Y173), the β-strand XVI (Y249), the loop between β-185 strands XVIII and XVIIII (R285), the lariat loop (H295) and the C-terminal swapping region (F388), led to 186 unambiguous assignment of NMR peaks between -0.3 ppm and 0.3 ppm in the 1 H-NMR spectrum (Figure 3b , 187 Figure S6 -S7 and Table S4 ). These positions were proposed to be associated with specific arrestin functions, 188 including receptor or IP6 interactions, or the activation of downstream ERK or AP2 but have never been fully 189 characterized by biophysical methods (Table S3 ). Therefore, TMSiPhe-containing β-arrestin-1 proteins provide a 190 useful tool for monitoring conformational changes in arrestin in response to receptor activation or other stimuli. 191 For example, the 1 H-NMR spectrum of native β-arrestin-1 F388-TMSiPhe exhibits a peak at -0.05 ppm, which can 192 be easily identified. By contrast, when another UAA, O-tert-butyltyrosine 13,31 , was genetically encoded into the 193 same position, the peaks for which cannot be assigned due to strong overlap with the methyl signals from the 194 protein ( Figure S8 ). Notably, in response to stimulation with increased concentrations of phospho-vasopressin-2 195 receptor-C-tail peptide (V2Rpp), the peak at -0.05 ppm gradually disappears, whereas a 1 H-NMR peak at 0.15 ppm 196 appears, reflecting the transition of the "inactive" arrestin conformation to an "active" arrestin conformation at the 197 F388 position, through dislodgement of this specific C-terminal swapping segment (Figure 3c and 3d) . Moreover, 198 the Scatchard plot for the titration experiment performed to examine the binding of V2R-phospho-C-tail to β-199 arrestin-1 exhibits a straight line with a regression coefficient of 0.99. The calculated KD value for the interaction 200 of V2Rpp with β-arrestin-1 was 6.9 ±0.2 μM (Figure 3e and Figure S9 ). Here, we demonstrate that while the genetic 201 incorporation of TMSiPhe introduce little perturbation to the target protein, it can be used as a convenient tool for 202 determining protein/peptide binding affinities. Since the 1D 1 H-NMR spectra contain only two peaks which 203 represent the "active" and "inactive" conformation, it takes no effort to perform NMR spectra assignment. 204 Moreover, since 1 H-NMR is easily accessible to most universities, our method is broadly applicable to most 205 biochemistry laboratories, without requiring for a strong expertise in NMR spectra assignment and 206 multidimensional NMR experiments. Arrestin is known to be activated via both receptor-phosphorylation and active seven transmembrane 7TM 212 core 8,12,15-18,32-37 ( Figure 4a ). While the recent rhodopsin/visual arrestin complex structure has provided a model of 213 the interactions of the receptor core with arrestin at an atomic resolution 37 , there is little structural information 214 regarding receptor core-induced structural rearrangement of arrestin at the residue level due to technological 215 difficulties in distinguishing the contributions of the receptor core, the receptor-phospho-tail, or the linker and 216 arrestin mutant used in the crystal structures individually, as well as the large amount of the receptor complex 217 required for structural delineation. 218
Thus, incorporation of TMSiPhe at specific positions in arrestin might facilitate detection of ligand-induced degree twist between the N-and C-domains of the protein (Figure 4a ). In the inactive state, the N-and C-domains 221 of β-arrestin-1 are tethered by the polar core, which is composed of the extensive charged interactions of Asp26, 222 Arg169, Asp290, Asp297 and Arg393 ( Figure S10 ). Disruption of the salt bridge between Asp297 and Arg393 and 223 that between Asp304 and Arg382, as well as the equivalent rhodopsin-visual arrestin interactions between Asp296 224 and Arg175 and Asp303 and Arg382, are known to activate arrestin 37 ( Figure S10 ). Notably, the results of recent 225 molecular dynamics studies have indicated that the rotation of Asp296 of visual arrestin (Asp290 in β-arrestin-1) 226 is closely associated with interdomain twisting. We therefore incorporated TMSiPhe at the H295 position, which 227 is close to both D290 and D297 of β-arrestin-1, to monitor the receptor-induced conformational changes in the 228 polar core (Figure 4a-4b and Figure S10 ). Specific incorporation of TMSiPhe at the H295 position in β-arrestin-1 229 did not impair the structural integrity of the protein, as H295-TMSiPhe-β-arrestin-1 exhibited normal activation in 230 response to the V2-receptor-phospho-tail interaction ( Figure S11 ). For structural validation of the TMSiPheRS 231 study with H295-TMSiPhe-β-arrestin-1, we performed 1 H-NMR measurements using the conditions for the crystal 232 structures of β-arrestin-1 in both the inactive apo-arrestin and in active arrestin stabilized by vasopressin 2 receptor 233 phospho-tail (V2Rpp) and the conformationally selective antibody Fab30 35 . Notably, in the "two-step arrestin 234 recruitment model of the receptor", V2Rpp/β-arrestin-1 mostly exhibited the "hanging" mode, whereas the 235 phospho-receptor/β-arrestin-1 complex encompassing the core interaction represented the "snuggly" 236 mode 32,35 ( Figure 4a ). Superimposition of the inactive and active arrestin structures revealed that both the "hanging" 237 and "snuggly" modes of active arrestin had similar conformations at the H295 position, differing significantly from 238 the modes of inactive arrestin, which featured considerable movement of the lariat loop ( Figure 4b ). 239
In the inactive state, the 1D 1H-NMR spectrum of H295-TMSiPhe-β-arrestin-1 contained mainly one peak at 240 0.25 ppm, which was designated S1 (Figure 4c ). Upon the addition of increasing the concentration of V2Rpp, the 241 peak volume of S1 gradually decreased, accompanied by the growth of a new peak at 0.15 ppm, which was 242 designated S2. The 1D 1 H-NMR spectrum obtained with a saturating concentration of V2Rpp mainly exhibited an 243 S2 peak, indicating that S2 represented an active state of H295TMSiPhe, whereas S1 represented the inactive state 244 of β-arrestin-1 H295TMSiPhe (Figure 4b and 4c ). 245 We then inspected the conformational change at the H295 site in response to occupation of the receptor by a 246 panel of ligands with the same phospho-receptor-tail by using the β2 adrenergic receptor (β2AR) as a prototypic 247 model. As previously described, we obtained the phospho-β2AR-V2-tail chimera (ppβ2V2R) by stimulating Sf9 248 cells with ISO (Isoproterenol), a low-affinity ligand, before harvesting the cells and washing out the residual ligands 249 by affinity chromatography 38 . The purified ppβ2V2R was then incubated with various ligands and then used to 250 form a stable receptor/arrestin complex by further incubation with β-arrestin-1 and the conformationally selective 251 antibody fragment Fab30 ( Figure S12 ). Complex formation was verified by size-exclusion chromatography, and 252 1D 1 H-NMR was performed to monitor changes in the NMR signal ( Figure 4d ). Application of the arrestin active 253 conformation stabilizing Fab30 alone had no significant effect on the NMR spectrum of β-arrestin-1 H295TMSiPhe 254 ( Figure S13 ). Notably, upon incubation with ppβ2V2R and Fab30, a new NMR signal appeared at 0.07 ppm 255 (designated S3), which was associated with the decrease in the S1 peak ( Figure 4d and Figure S14-S15). Therefore, the complex with the ppβ2V2R, as observed in the crystal structure of the rhodopsin/visual arrestin complex. 1 H-259 NMR chemical shift is sensitive to the change of hydrogen bonding, local dielectric constant, and nearby aromatic 260 residues. Thus, NMR chemical shifts are sensitive to subtle structural changes in proteins. The S2 and S3 states 261 have similar loop structures, but subtle differences in sidechain orientation are obvious ( Figure 4b) . 262 We next examined the 1D 1 H-NMR spectrum of the ppβ2V2R/β-arrestin-1 complex in the presence of various 263 β2AR ligands exhibiting different pharmacological activities. Importantly, while the S1 state population of 264
H295TMSiPhe decreased upon addition of various agonists, including the full agonists ISO and BI-167107, or the 265 partial agonists Clenbuterol (Clen) and Salmaterol (Salm), the S3 state population increased ( Figure 4e and Figure  266 S15-S16). By contrast, the neutral antagonist Alprenolol (Alp) showed no effect on the S3 state, whereas the inverse 267 antagonist ICI-118551 (ICI) reduced the population of the S3 state ( Figure 4d and Figure S15 ). Moreover, the 268 volume of the S3 state corresponds to the potency of the ligand in inducing receptor internalization ( Figure 4e and 269 Figure S17 ). These trends mirrored the ability of the ligand to promote torsion between helix VI and helix III, a 270 hallmark of the conformational changes in the receptor 7-transmembrane core induced by agonists ( Figure 4f and 271 Figure S18 ). Overall, the 1D 1H-NMR spectrum of β-arrestin-1 H295TMSiPhe indicated that the conformational 272 changes in the polar core of the arrestin in response to ligand properties are associated with the abilities of these 273 ligands to promote receptor internalization in the presence of the same receptor (Figure 4e-4f and Figure S17 ). To confirm that the observed S3 signal in the 1D 1H-NMR spectrum was dependent on the interaction of β-279 arrestin-1 with the receptor core, we performed a competition assay using a well-characterized binding partner of 280 the receptor 7-transmembrane core, namely, the Gα protein C-tail (Gα-CT) ( Figure 5a ). Moreover, direct 281 engagement of the β-arrestin-1 finger loop and Gα-CT of G-protein serves as a major interaction interface with the 282 receptor 7-transmembrane core, which was supported by recent cross-linking and electron microscopic studies 35,39-283 41 . Therefore, we prepared the ISO/ppβ2V2R/β-arrestin-1/Fab30 complex in the presence of Gα-CT. Incubation 284 with Gα-CT did not disrupt the ISO/ppβ2V2R/β-arrestin-1/Fab30 complex, as the presence of Gα-CT did not alter 285 the SEC (size-exclusion chromatography) profile ( Figure 5b ). Notably, while incubation of Gα-CT with β-arrestin-286 1-H295-TMSiPhe led to no significant alteration in the 1D 1 H-NMR spectrum, addition of Gα-CT with the 287 ISO/ppβ2V2R/β-arrestin-1/Fab30 complex significantly decreased the S3 state and increased the S1 state, 288 suggesting that the observed S1 state reduction was mainly due to elimination of the receptor core interaction with 289 β-arrestin-1 by the binding of Gα-CT ( Figure 5c ). Because H295 is located in the close proximity to the polar core 290 residues Asp290 and Asp297 of β-arrestin-1, the 1D 1 H-NMR spectrum obtained from Gα-CT competition 291 experiments with H295-TMSiPhe-β-arrestin-1 confirmed that the agonist ISO was able to induce conformational ppβ2V2R and arrestin, we next performed a V2R-phospho-C-tail competition experiment ( Figure 5d ). Incubation 295 of the excess V2Rpp led to the dissociation of ppβ2V2R from the ISO/ppβ2V2R/β-arrestin-1/Fab30 complex, as 296 suggested by the SEC results ( Figure 5e ). However, the active conformation of H295 persisted even when the 297 arrestin dissociated from the receptor, as indicated by the maintenance of the amplitude of the S3 state in the 1D 298 1 H-NMR spectrum (Figure 5f ). These data suggested that the S3 conformational state of H295 in arrestin do not 299 simply reflect the propensities of the ligands for stabilization of the GPCR-arrestin complex, but is a consequence 300 of the receptor-core-arrestin interaction. Furthermore, maintenance of the S3 activation state of arrestin even after 301 dissociation from the receptor was consistent with the hypothesis proposed in recent cellular studies, which 302 suggested that an arrestin activation cycle occurred in response to activation by the receptor. We next extended the TMSiPhe technology to study the conformations of other β-arrestin-1 sites associated 307 with specific arrestin functions. We selected the R285 position of β-arrestin-1, which was hypothesized to play 308 important roles in interaction with ERK 42 (Figure 3a and Table S3 ). Notably, superimposition of the structures of 309 inactive β-arrestin-1 structure and the rhodopsin-visual arrestin complex indicated that R285 assumed a highly 310 exposed and extended conformation (Figure 6a ), suggesting that receptor interaction may regulate conformational 311 change at this specific site. 312 We therefore incorporated TMSiPhe at the R285 site of β-arrestin-1 and monitored the change in the 1H-NMR 313 spectrum in response to the binding of ppβ2V2R engaged with different ligands (Figure 6b and Figure S19-S21). 314
The functional integrity of R285TMSiPhe-β -arrestin-1 was validated, and Fab30 was used to stabilize the 315 ppβ2V2R/β-arrestin-1 complex without perturbation in the NMR spectrum ( Figure S11 and S19). Application of 316 ppβ2V2R without or with different ligands eliminated the original NMR peak at 0.158 ppm but broadened the 317 conformational distributions from 0.03 ppm to 0.10 ppm (Figure 6b-6c and Figure S21 ). At least 4 different 318 conformational states of the ppβ2V2R/β-arrestin-1-R285TMSiPhe/Fab30 complex were discerned in the presence 319 of different ligands. Notably, β-arrestin-1 alone also has small but visible peaks in the 0.03 ppm-0.10 ppm region, 320
indicating that a conformational selection model may also be suitable for description of the receptor-induced 321 conformational change at the β-arrestin-1-R285 position. In particular, addition of any receptor complexes without 322 or with different ligands all produced a similar peak at 0.09 ppm (R0 state), indicating that this conformational state 323 may be mainly due to the binding of the receptor-phospho-tail but is not significantly affected by the receptor core 324 interaction ( Figure 6b and Figure S21 ). 325
The ligands mostly changed the distribution of NMR peaks from 0.04 ppm to 0.07 ppm, which included 3 326 conformational states derived by simulation, namely, R1a-b (0.065-0.068 ppm) and R2 (0.05 ppm). Although 327 application of the neutral antagonist Alp and the agonist ISO had no significant effect on the NMR peak at R1a 328 (0.065 ppm), application of the long-term covalent agonist BI caused a small but significant low field shift of R1a 329 to R1b (0.068 ppm). 330
The application of partial and inverse agonists caused complex conformational changes. Whereas Clen significantly diminished the distribution of the R1a state and promoted the appearance of a high-field R2 state, the 332 engagement of the receptor with the G-protein-biased partial agonist Sal and the inverse agonist ICI almost 333 completely eliminated the presence of the R1 states and facilitated the emergence of the R2 states (Figure 6b -6c 334 and Figure S21 ). As Sal and ICI are not known for arrestin-dependent ERK signaling, the appearance of the R2 335 conformational states of the β-arrestin-1 R285 position may not contribute to ERK activation in response to 336 receptor/arrestin complex interactions. Taken together, multiple conformational states of the β-arrestin-1 R285 337 position were detected by TMSiPhe in response to different β2AR ligands, which was not strictly correlated with 338 the ability of these ligands in either the activation of G-protein (agonists vs. antagonists) or arrestin-mediated 339 receptor internalization, indicating that each specific receptor ligand may lead to a distinct conformational state at 340 a specific arrestin site, which contributes to the selective functions of these ligands. Despite the broad applications of NMR in the characterization of protein structure and dynamics, it has 345 remained very challenging to use NMR to study large transmembrane protein complexes, whose NMR spectra 346 exhibit severe line broadening and overlapping resonance. While site-specific protein labelling with 1D NMR probe 347 has provided an exciting new method for the investigation of membrane protein complex 8,9,43-45 , one limitation of 348 cysteine-mediated chemical labeling is that it only allows access to the surface residues of proteins, preventing 349 observation of the important dynamic interactions that occur within protein hydrophobic cores. Moreover, to 350 achieve site-specific labelling, all other surface-exposed cysteine residues must be mutated, which may cause 351 significant perturbation to protein structure and function. By contrast, UAA incorporation through genetic code 352 expansion allows labeling of desired residues at both exposed and internal sites. For example, through genetic code 353 expansion, we have developed a method to efficiently incorporate the UAA difluorotyrosine (F2Y) into proteins of 354 interest, enabling us to study how different receptor phospho-barcodes localized in the receptor C-tail regulate 355 distinct functionally selective arrestin conformations 12, 16 . Despite this significant progress, 19 F-NMR requires large 356 amount of protein (usually more than 100 µM), and each measurement generally takes more than 12 hours. 357 Therefore, the development of a 1D NMR probe for the examination of the conformational dynamics of 358 transmembrane protein complexes using a low concentration of protein is urgently needed. 359
Through genetic code expansion in E. coli, we have achieved the highly selective and efficient labelling of 360 trimethylsilyl (TMS) group in proteins, and demonstrated its broad applicability to investigate multiple 361 conformation state of large membrane protein complexes. The efficient and selective incorporation of TMSiPhe 362 was verified by both mass spectrometry and crystallography. Using this method, we were able to detect the dynamic 363 conformational changes in membrane protein complex (molecular weight ~ 150 kDa) at the residue level, using a 364 low protein concentration ranging of 5 μM, and a short spectra accumulation time of 20 min. Key to this 365 advance is the evolution of TMSiPheRS, a specific tRNA synthetase which selectively recognizes TMSiPhe to 366 facilitate its genetic incorporation into proteins. receptor core engagement, a process important for GPCR signaling. Previous studies by us and others have provided 369 important mechanistic insights, demonstrating that receptor-phospho-barcodes present in the receptor-C-tail play 370 pivotal roles in the determination of selective arrestin functions 12, [16] [17] [18] 32, 33, 35, 46 . An important model for the 371 development of arrestin-biased GPCR ligands is that ligands for GPCRs can cause conformational changes in 372 arrestin via direct receptor core/arrestin interactions regardless of the C-terminal phosphorylation pattern. Notably, 373 the rhodopsin/visual arrestin complex crystal structure provided knowledge of receptor core/arrestin interactions at 374 the atomic level 3 , and the FlAsH-BRET assays revealed that different receptor activation resulted in diverse arrestin 375 conformations in cells 17 . However, dynamic information and high-resolution data regarding conformational 376 changes in arrestin dictated by different receptor ligands via the receptor core/arrestin interaction remains 377 undetermined, likely due to the low resolution of cellular methods and the difficulty of the application of 378 biophysical approaches for the study of receptor complex systems. Here, through the residue-specific 379 conformational detection method using TMSiPheRS, as well as cellular internalization assays, our results reveal 380 that ligands directed structural alterations of the 7-helix transmembrane core of the GPCR interacts with arrestin to 381 cause conformational change in the arrestin polar core, and the extent of which is correlated with the internalization 382 ability of the receptor/arrestin complex. 383
In addition to structural alterations in the polar core, we used TMSiPhe to examine the conformational changes 384 that occurred at the R285 position of β-arrestin-1, a site associated with ERK activation 42 . Importantly, 385
R285TMSiPhe assumed multiple conformations in response to the engagement of different ligands with β2V2R 386 harboring the same phosphorylated receptor C-tail. Importantly, the conformational states of the 285 site are not 387 directly correlated to the functions of these β2AR ligands in either Gs activation or receptor internalization, 388
indicating that different ligands of the same receptor were able to regulate distinct arrestin conformations at specific 389 arrestin sites, which may be correlated with selective functions. Notably, the arrestin-ERK interaction may involve 390 multiple interfaces. Therefore, the conformational changes in the R285 site observed by TMSiPhe likely contribute 391 to, but are not the sole determinants of, arrestin-mediated ERK activation. 392
In summary, we have achieved the efficient and selection incorporation of TMSiPhe into protein in E. coli, to 393 facilitate rapid detection of the dynamic conformational changes in 150 kD membrane protein complexes, using 394 1D 1 H-NMR. Due to the high 1 H-NMR signal intensity, and unique up-field chemical shift of the TMS group, good 395 1D 1 H-NMR spectra can be acquired using only 5 μM of protein, and 20 min accumulation time. Using this handy 396 and powerful approach, we identified the ligand-induced and functionally relevant arrestin conformational states 397 via receptor core engagement 47 . We expect this method will be broadly applicable to biochemistry laboratories to 398 decipher dynamic protein interaction mechanism under physiological conditions. Iodine (catalytic amount) was added to the mixture of Magnesium turning (2.67 g, 110 mmol) and 4-bromotoluene 427 1 (1.71 g, 10 mmol) in 80 ml of dry tetrahydrofuran (THF (containing 0.002% water). The reaction was started by 428 heating, then 4-bromotoluene (1) (15.4 g, 90 mmol, dissolved in 20 mL of dry THF) was slowly added in a drop 429 wised manner. After refluxing for 4h, the reactions were kept slight boiling by the drop wised addition of trimethyl 430 chlorosilane (12.7 ml, 110 mmol). The mixture were reflux for another 2 h, followed by stirring at room temperature 431 and quenching with 500 ml ice-cold water. The mixture was extracted with ethyl acetate (EA，100 mL*3) and the 432 organic layers were combined and subsequently washed with brine (100 mL*3). The organic layer was then dried 433 over Na2SO4, filtered and evaporated. The residue was chromatographed by silica gel with petroleum ether (PE) 434 as an eluent. The colorless liquid (14.3 g) was obtained with 87% yield. 
Synthesis of (4-(bromomethyl) phenyl) trimethylsilane (3) 437
Trimethyl(4-tolyl) silane (2) (3.28 g, 20 mmol) was dissolved in tetrachloromethane (CCl4, 50 mL, A.R. grade) at 438 room temperature. N-bromosuccinimide (NBS, 3.56 g, 20 mmol) and azodiisobutyronitrile (AIBN, 0.33 g, 2 mmol) 439 was added. The mixture was stirred with 4hours refluxing, followed by vacuum condensation. The residue was 440 used for the next step without further purification. dissolved in 60 ml DMSO and the mixture was stirred at 10℃ for 20 min. The mixture was added with (4-445 (bromomethyl) phenyl) trimethylsilane (3) (12.15 g, 50 mmol) and kept stirring for 1 h, following by adding 720 446 ml of ice-cold water and then extracting with EA (200 ml*3). The organic layers were combined and were 447 subsequently washed with brine (100 mL*3). The organic layer was then dried over Na2SO4, filtered, and 448 concentrated under reduced pressure. NaOH aqueous 30 ml. The mixture was then stirred for overnight at room temperature, followed by adding 300 ml 461 of PE. Then the aqueous phase was added to 600 ml of 0.1N HCl aq in a drop wise manner with stirring. A lot of 462 white solid was precipitated from the solution. The product was filtered and dried under vacuum to afford the 2-463 amino-3-(4-(trimethylsilyl) phenyl) propanoic acid (5.6 g, 78% 
Genetic selection of the mutant synthetase specific for TMSiPhe (TMSiPheRS). 469 470
The pBK-lib-jw1 library consisting of 2×109 independent TyrRS clones was constructed using standard PCR 471 methods. E. coli DH10B harboring the pREP(2)/YC plasmid was used as the host strain for positive selection. Cells 472 were transformed with the pBK-lib-jw1 library, recovered in SOC for 1 h, washed twice with glycerol minimal 473 media with leucine (GMML) before plating on GMML-agar plates supplemented with kanamycin, harboring the negative selection plasmid pLWJ17B3, recovered for 1 h in SOC and then plated on LB-agar plates 478 containing 0.2% arabinose, 50 g/ml ampicillin and 50 g/ml kanamycin. The plates were then incubated at 37 °C 479 for 8-12 hours, and pBK-lib-jw1 DNA from the surviving clones was extracted as described above. The library 480 underwent another round of positive selection, followed by a negative selection and a final round of positive 481 selection (with chloramphenicol at 70 g/mL). At this stage, 96 individual clones were selected and suspended in 50 482 L of GMML in a 96-well plate, and then replica-spotted on two sets of GMML plates. One set of GMML-agar 483 plates was supplemented with tetracycline (15 g/mL), kanamycin (50 g/mL) and chloramphenicol at concentrations 484 of 60, 80, 100 and 120 g/mL with 1 mM TMSiPhe. The other set of plates were identical but did not contain Phe, and the chloramphenicol concentrations used were 0, 20, 40 and 60 g/mL. After 60 h incubation at 37 °C, one 486 clone was found to survive at 100 g/mL chloramphenicol in the presence of 1 mM TMSiPhe, but only at 20 g/mL 487 chloramphenicol in the absence TMSiPhe. The plasmids encoding sfGFP Y182TMSiPhe in pET22b vector was co-transformed with pEVOL-TMSiPheRS 507 into BL21(DE3) E.coli cells. Cells were amplified in LB media supplemented with ampicillin (50 µg/mL) and 508 chloramphenicol (30 µg/mL). Cells were then grown to an OD600 = 0.8 at 37°C . After induction14 hours at 30°C 509 with 0.2% L-arabinose, 0.3 mM IPTG and 0.5 mM TMSiPhe, cells were harvested by centrifugation. The cells 510
were lysed by French pressing in buffer containing 50 mM HEPES, pH 7.5, 500 mM NaCl. The supernatant was 511 collected and incubated with Ni-NTA column for 2 hours at 4°C, filtered, and washed with wash buffer containing 512 concentrated to 20 mg/mL. The crystal of sfGFP Y182TMSiPhe were obtained at 16℃ by the hanging drop vapor 516 diffusion by mixing 1 µL protein sample with equal volume of mother liquor containing 10% PEG 6,000 and 2.0 517 M Sodium chloride. The crystal appeared within one week. Crystals were then flash-frozen in liquid nitrogen in 518 10% PEG 6000, 2.0 M Sodium chloride and 20% glycerol. The cells were lysed by French pressing in buffer A (50 mM Tris-HCl, pH 8.0, 150 mM NaCl) and the lysate was 568 batch binding with 300 μL Ni-NTA column (GE Healthcare, USA). After an extensive washing with buffer A, the 569 target protein was eluted using 300mM imidazole in buffer A. These proteins were subsequently purified by size 570 exclusion column Superdex 75 and the buffer was exchanged to buffer B (50 mM Tris-HCl, pH 7.5, 150 mM NaCl). 571 572 Expression and purification of β2V2R 573 574 FLAG-β2V2R and GRK2-CAAX were co-expressed in baculovirus-infected insect cells (Sf9) using the Bac-to-575 Bac baculovirus Expression System as previously described 38 . Cells were stimulated with ISO(10 μM)and 576 harvested at 64 or 72 h after infection. The cell pellets were stored at -80℃. Cell membranes were disrupted by 577 thawing frozen cell pellets in 300 ml of hypotonic buffer C (10 mM HEPES pH7.5, 20 mM KCl and protease 578 inhibitor cocktail) and homogenized using a Dounce homogenizer repeated plunging. The membrane fraction was 579 separated from the lysate via ultracentrifugation (42,000 rpm speed for 40 min in Ti45 rotor). The pellet was washed 580 3-4 times with a high osmotic buffer D containing 1.0 M NaCl in the above buffer C, and centrifuge as above. The 581 pellet was subsequently solubilized with 1% n-decyl-β-D-maltopyranoside and (DDM, Anatrace) 0.2%CHS (sigma) 582
in buffer E (50 mM HEPES pH7.5, 1 M NaCl). The solubilized membrane fraction was then purified by flag-M1 583 resin (sigma) affinity chromatography in buffer F (20 mM HEPES pH7.5, 150 mM NaCl, 0.1%DDM, 0.02% CHS). 584
Finally, the sample buffer was exchanged to buffer G (20 mM HEPES pH7.5, 150 mM NaCl, 0.01%LMNG, 0.002% 585 CHS) using a PD-10 desalting column. Purified protein samples were used fresh in the experiments. 586
Superdex Exclusion Chromatography 588 589
The purified ppβ2V2R (30 μM) were stimulated with different ligands (60 μM) and then incubated with β-arrestin-590 1 H295TMSiPhe (10 μM) for 30 min at 25°C. Then Fab30 (20 μM) was then added to the mixture and the complex 591 was allowed to form for 1h at 25 °C. The ligand/ppβ2V2R/β-arrestin-1 H295TMSiPhe-Fab30 complex were 592 concentrated and then purified by Superdex 200 increase in 20 mM HEPES pH7.5, 150 mM NaCl, 0.01% LMNG, 593 0.002% CHS and corresponding ligand (60 μM). The yield of the purified complexes were approximately 50%, 594 and the purities were judged by size exclusion chromatography and the electrophoresis. 595 596 NMR experiment 597 598 β-arrestin-1 TMSiPhe mutants prepared for NMR analysis were quantified with BCA protein assay kit and diluted 599 with buffer B (containing10% D2O)to 5~20 μM. All 1D 1H NMR spectra were recorded with typical total 600 experimental times 8~15 min at 25°C, on an Avance 950 MHz spectrometer with cytoprobe (Bruker, Billerica, 601 MA). The spectra were processed and analyzed with the program ZGGPW5 (NS = 32; DS = 4; SW = 20ppm; 602 AQ = 1.93 s; D1 = 1s. The number of scans was adjusted to the relative protein concentration in each experiment. 603
The chemical shift of the signal peak was determined by reference to D2O (4.68ppm). 604
Binding of the V2Rpp to the β-arrestin1 was assessed using β-arrestin1-F388TMSiPhe (20 μM), in the presence of 605 V2Rpp at a gradient increased concentration, in 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 10% D2O buffer on a 606
Bruker 950 MHz NMR spectrometer. The signal was normalized with Tris and integrated at shift -0.05 ppm after 607 auto baseline correction by MestReNova.9. Through calculating the ratio of the area of remaining Apo NMR peak 608 and the original concentration of each component, the complex state (Bound) concentration and free ligand(V2Rpp) 609 concentration were obtained for Scatchard plotting and one-site specific curve fitting. 610
Buffer for complex of ppβ2V2R/β-arrestin1/Fab30 1D1H NMR spectra was 20 mM HEPES, 150 mM NaCl, 0.01% 611 LMNG, 0.002% CHS, 10% D2O, pH 7.5, 60 μM ligand or control vehicle (diluted DMSO). The total recording 612 time for each experiment was 40 min. spectra were recorded using a Bruker 950 MHz NMR spectrometer at 25°C. The purification of Fab30 was performed as previously described 36 . M5532 E. Coli competent cells was 617 transformed with the plasmid containing Fab30 fragment and was cultured in the CRAP-Amp medium cultures in 618 2.8 L non-baffled flasks and grow for 18-24 hours at 30°C (200 rpm). These cells were pelleted and freeze with 619 liquid nitrogen, then stored at -80°C. The frozen cell pellets were thawed at room temperature and added with 15 620 mL of TES (Tris-EDTA-Sucrose) / pellet of 1 liter culture; resuspend, shaked for one hour on ice in cold room 621 platform shaker with 150 rpm (TES buffer: 200mM Tris pH=8.0; 0.5 mM EDTA, 0.5 M sucrose), followed by continue to shake 1h on ice. The solution was poured into 250 mL centrifuge bottles and spin in SLA 1500 rotor the cell lysate were incubated with Ni-NTA beads by 2-12 hours with a ratio of 500 μL beads/ 1 liter culture. The 626 beads were packed in a column and washed with 40 CV of cold buffer B (20 mM Tris-Hcl pH=7.55, 150 mM 627 NaCl), and then eluted with buffer C (20 mM Tris-HCl pH=7.55, 150 mM NaCl, 250 mM imidazole). 628 629 GST pull down assay 630 631 0.1 μM wild-type or mutant β-arrestin-1 was mixed with 0.5μM phospho-receptor-C-tail fragment (V2Rpp) and 632 incubated in binding buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 2 mM EDTA, 1 mM DTT) at 25°C for 30 633 min as previously described 12 . 1 μM GST-clathrin was then added and incubated for another hour. Subsequently, 634 10 μL GST beads were added into the mixture and the mixture was rolled at 4°C for 2 h. The GST beads were 635 collected by centrifuge and washed with wash buffer (binding buffer with 0.5% Tween20) for 4 times. After 636 removing the supernatant, the samples were re-suspended in 50 μL 2×SDS loading buffer and boiled for 10 min 637 before western blot. The method was carried out according to a previously published manuscript 52 . Purified receptors (β2AR-Δ5-642 Cys271+Trp135 )and mBBr (Invitrogen) were mixed at the same molarity in LMNG buffer (not containing CHS) 643 and incubated overnight on ice in the dark. Fluorophore-labeled receptors were obtained by gel filtration on a 644 desalting column equilibrated with LMNG/CHS buffer (20 mM HEPES, 150 mM NaCl, 0.01% LMNG, 0.002% 645 CHS, pH 7.5). 646
Fluorescence spectroscopy was measured on a Varioskan flash (Thermo Scientific) instrument with full wavelength 647 scanning mode at 25°C. 100 μL samples containing 0.2 μM bimane labeled β2AR in a MicroFluor 96-well plate 648 were excited at 390 nm, and the emission fluorescence was measured by scanning from 430 to 500 nm using a 2 nm 649 step . Each data point was integrated for 0.2 s. If the ligand was present, concentration of ligand was set for 5μM 650 and the incubation time was set for 15min.We corrected fluorescence intensity for background fluorescence from 651 buffer. Spectra were analyzed using the GraphPad Prism 5. 652 653 BRET assay 654 655 HEK293 cells seeded in 6-well plates were transfected with 0.5 μg BRET donor Flag-β2V2R-Rluc and 1 μg BRET 656 acceptor Lyn-YFP using polyethylenimine as previously described 21 . 24 h after transfection, the cells were detached 657 and distributed into 96-well plates at a density of ~25,000 cells per well. After another 24 h incubation at 37 °C, 658 the cells were washed twice with Tyrode's buffer (140 mM NaCl, 2.7 mM KCl, 1 mM CaCl2, 12 mM NaHCO3, 5.6 mM D-glucose, 0.5 mM MgCl2, 0.37 mM NaH2PO4 and 25 mM HEPES, pH 7.4) and stimulated with vehicle acid residues measured in aqueous solutions of the linear tetrapeptides Gly-Gly-X-Ala at pressures between 809 0.1 and 200 MPa. Biophys Chem 96, 129-140 (2002) . 810
55
Szczepek Full-length β-arrestin-1 protein was obtained by cotransfection with the β-arrestin-1 H295 881 TAG mutant plasmid and the pEVOL-TMSiPheRS plasmid, with TMSiPhe 882 supplementation of the culture medium. The purity of the protein was determined by 883 electrophoresis. The protein was subjected to trypsin digestion and analyzed by MS/MS. 884
These results unambiguously confirmed that TMSiPhe was selectively incorporated into β-885 arrestin-1 at the H295 position. m/z, mass/charge ratio. 886 (d) The 2Fo-Fc annealing omit map of sfGFP-Y182-TMSiPhe clearly shows the electron 887 density of TMSiPhe. The map was contoured at 1.1 σ. 888 (e) 1D 1 H NMR spectra for the β-arrestin-1 H295 TMSiPhe mutant were compared with those 889 for wild-type β-arrestin-1 cultured in the presence of TMSiPhe. The spectra were recorded in a 890 buffer containing 50 mM Tris-HCl (pH 7.5) and 150 mM NaCl at 25°C using a Bruker 950 group substituted amino acids in a protein were generally located in the high-field region (<0.55 894 ppm, blue area). arrestin-1 crystal structure (PDB: 1G4M). Orange, Y21 in the three elements; purple, Y63 in 915 the finger loop; blue, Y173 in the hinge region; cyan, Y249 in β-strand XVI; pink, R285, green, 916 H295 in the lariat loop; red, F388 in the C-terminal swapping segment. 917 (b) 1D 1 H NMR spectra of β-arrestin-1 labeled as described in (3a). The spectra were recorded 918 in a buffer containing 50 mM Tris-HCl (pH 7.5 and 150 mM NaCl at 25°C using a Bruker 950 919
MHz NMR spectrometer. The protein concentrations were 5~15 μM, and the total recording 920 time per spectrum was 6~15 min. The chemical shift for the TMSiPhe protein was less than 921 0.55 ppm. 922 (c) Cartoon illustration of the activation of β-arrestin-1 and movement of the C-terminal 923 swapping segment of β-arrestin-1. In response to the binding of an activator, such as the 924 phospho-vasopressin receptor C-tail (V2Rpp), the originally embedded C-terminal swapping 925 segment of β-arrestin-1 became highly solvent exposed, thus favoring binding to downstream 926 signaling proteins, for example, clathrin or AP2 (adaptor protein 2). This conformational 927 transition could be monitored by incorporation of TMSiPhe at the F388 position of β-arrestin-gradually decreased in intensity, while the peak representing the active state (0.15 ppm) steadily 932 increased in intensity. The spectra were recorded in a buffer containing 50 mM Tris-HCl (pH 933 7.5) and 150 mM NaCl at 25°C using a Bruker 950 MHz NMR spectrometer. The inactive β-arrestin-1 structure is depicted in gray; the V2Rpp/β-arrestin-1 complex is in 954 green; and the rhodopsin-arrestin complex is in red. The two active arrestins have similar 955 conformations at the H295 position, differing significantly from the pose in the inactive arrestin 956 structure. 957 (c) 1D 1 H NMR spectra of β-arrestin-1-H295-TMSiPhe in response to titration with V2Rpp. 958
Two distinct peaks were observed. With increasing concentrations of V2Rpp, the peak at 0.25 959 ppm decreased (representing the S1 state), whereas a new growing peak was observed at 0.15 960 ppm (representing the S2 state). excess Gα C-terminus (Gα-CT), which has been described in previous reports 55 . The interaction 987 between β-arrestin-1 and the GPCR TM core was abolished via steric hindrance by Gα-CT. β-988
Arrestin-1 still interacts with the phosphorylated GPCR C-terminal tail and thus forms a 989 complex with the receptor. transformation from S1 to S3 induced by the ISO/ppβ2V2R/β-arrestin-1/Fab30 complex was 998 significantly weakened by the addition of Gα-CT, suggesting the observed S3 state reduction 999 was mainly due to the elimination of the receptor core interaction with β-arrestin-1 by the
